Sedivention secures € 800,000 pre-seed

Marc Nemitz Marc Nemitz | 18.11.2024

Sedivention aims to revolutionize the fight against obesity with a newly developed cryo-catheter. The minimally invasive treatment aims to permanently reduce the feeling of hunger and is being supported by HTGF with €800,000.

Munich, November 18, 2024 - Medtech startup Sedivention has successfully closed €800,000 in pre-seed funding from High-Tech Gründerfonds (HTGF) to develop a novel treatment for obesity. The Strasslach-based company is working on a minimally invasive medical device that provides a one-time treatment for long-term weight loss support. The funding will be used to drive forward the further development of the product and initial preclinical studies.

Obesity - a growing global health crisis

The figures are alarming: obesity already causes around 3.7 million deaths worldwide every year and the number of people affected is constantly increasing. According to current forecasts, the disease will affect around 1.5 billion people by 2030. Lack of exercise, a high-calorie diet, genetic factors as well as psychological strain, lack of sleep and stress are major contributors to this problem. With increasing body weight, many people lose the ability to self-regulate hunger and satiety, a disorder in which the vagus nerve plays a central role.

Cryo-catheter as an outpatient solution

Sedivention is focusing on a new method of treating obesity that specifically targets the vagus nerve. To this end, the company is developing a cryo-catheter that is minimally invasive and obliterates the gastric branches of the vagus nerve, thereby influencing signal transmission between the stomach and brain. This outpatient, one-off intervention, which is similar to a gastroscopy, only takes a few minutes and could be a cost-effective alternative to surgery or long-term drug therapies. In addition to weight loss, the method also promises positive effects on secondary diseases such as diabetes and high blood pressure.

Obesity is not a consequence of indiscipline, but a disease in its own right. We help people to lose weight - without surgery, without implants and without lifelong medication.

Dr. Ute Nollert, the founder of Sedivention

Funding for product development and preclinical studies

The developed prototype has already been successfully tested for safety and efficacy. With the support of HTGF, Sedivention can now press ahead with product development and take the next steps towards market maturity. These next steps include the first preclinical studies to further validate the functionality and safety of the device.

We are convinced of the idea and approach of Sedivention's novel therapy and are pleased to accompany the company in its next steps

Dr. Jan Engels, Investment Manager at HTGF

HTGF is one of the leading early-stage investors in Europe and contributes its expertise and network to support young companies in their early stages.

Innovation from Bavaria

Sedivention GmbH was founded in 2021 by Dr. Ute Nollert and an experienced team of engineers and doctors in Straßlach near Munich. They have already achieved an initial breakthrough with their prototype and are now working on further development to bring their minimally invasive obesity therapy to the market. The startup's long-term goal is to offer a cost-effective, safe and outpatient solution for people with obesity that represents an alternative to conventional treatment methods and could improve the lives of many people worldwide.

With this therapy, the startup could make a significant contribution to tackling the global obesity epidemic. The HTGF funding enables the next decisive steps towards the development of a market-ready product that could offer an outpatient, low-risk solution for those affected in the future.


Like it? Please spread the word:


Newsletter

Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.

LinkedIn Connect

Take care, give care

Did this news inform or entertain you? Then we would be happy if you tell your network about it.

Share on Linkedin Share on Facebook Share on Xing

Related companies

High-Tech Gründerfonds
Investor 2005 Bonn High-Tech Gründerfonds High-Tech Gründerfonds (HTGF) is Germany's most active early-stage investor for young, innovative technology start-ups.

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen

Similar posts